MedPage Today on MSN
Trial Patient Dies After Receiving CRISPR Gene Therapy
A patient with transthyretin amyloidosis (ATTR) who received the investigational gene therapy nexiguran ziclumeran (nex-z) in ...
BioSpace
Patient Dies After Receiving Intellia’s CRISPR Gene Therapy Candidate
The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex ...
Intellia tumbles after patient dies following Crispr treatment
The Cambridge-based biotech company is studying the use of Crispr, the Nobel Prize-winning gene-editing technology, to treat ...
Becker's Hospital Review
Intellia trial participant dies after severe liver reaction
Intellia Therapeutics temporarily paused dosing and screening for its phase 3 Magnitude and Magnitude-2 trials of Nex-z following a patient hospitalization, according to an Oct. 27 news release. The ...
Fierce Biotech
Patient dies after receiving Intellia's CRISPR therapy
The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...